Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Rosen · SciRah

Researcher profile · Semantic Scholar

L. Rosen

Share profile

L. Rosen — researcher profile on SciRah

h-index: 50
Works: 262
Citations: 14K

Most-cited papers

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
A. Patnaik, L. Rosen, S. Tolaney, A. Tolcher +20 more
2016Cancer Discovery599 citations
Semantic Scholar
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
S. Leijen, R. van Geel, A. Pavlick, R. Tibes +12 more
2016Journal of Clinical Oncology222 citations Open access
Semantic Scholar
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
A. Daud, M. Ashworth, J. Strosberg, J. Goldman +14 more
2015Journal of Clinical Oncology174 citations Open access
Semantic Scholar
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
L. Rosen, I. Jacobs, R. Burkes
2017Targeted oncology141 citations Open access
Semantic Scholar
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
J. Goldman, R. Raju, G. Gordon, I. El-Hariry +8 more
2013BMC Cancer113 citations Open access
Semantic Scholar
Clinical Outcomes of Patients with Advanced Gastrointestinal Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-use Trial of Sunitinib
P. Reichardt, Yoon-Koo Kang, P. Rutkowski, J. Schuette +14 more
2015Cancer108 citations Open access
Semantic Scholar
Endoglin for Targeted Cancer Treatment
L. Rosen, M. Gordon, F. Robert, D. Matei
2014Current Oncology Reports92 citations
Semantic Scholar
A phase 1 study of the heat shock protein 90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft tissue sarcomas
A. Wagner, R. Chugh, L. Rosen, J. Morgan +6 more
2013Clinical Cancer Research79 citations Open access
Semantic Scholar
First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors.
David C. Smith, L. Rosen, R. Chugh, J. Goldman +7 more
201378 citations
Semantic Scholar
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
J. Infante, R. Korn, L. Rosen, P. LoRusso +9 more
2017British Journal of Cancer73 citations Open access
Semantic Scholar
A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
G. Shapiro, L. Rosen, A. Tolcher, J. Goldman +13 more
201373 citations
Semantic Scholar
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
L. Rosen, P. LoRusso, Wen W. Ma, J. Goldman +9 more
2016Investigational new drugs72 citations Open access
Semantic Scholar
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
A. Tolcher, P. LoRusso, Jennifer Arzt, T. Busman +6 more
2015Cancer Chemotherapy and Pharmacology66 citations
Semantic Scholar
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
L. Rosen, J. Goldman, A. Algazi, P. K. Turner +7 more
2016Clinical Cancer Research62 citations Open access
Semantic Scholar
An Open Label Phase 1b Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
M. Gordon, F. Robert, D. Matei, D. Mendelson +10 more
2014Clinical Cancer Research59 citations Open access
Semantic Scholar
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
A. Tolcher, J. Goldman, A. Patnaik, K. Papadopoulos +13 more
2014European Journal of Cancer56 citations
Semantic Scholar
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
K. Papadopoulos, M. Johnson, A. C. Lockhart, K. Moore +14 more
2019Clinical Cancer Research55 citations Open access
Semantic Scholar
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors
L. Rosen, R. Wesolowski, R. Baffa, Kai H. Liao +4 more
2019Investigational new drugs50 citations
Semantic Scholar
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)
M. Fakih, W. Harb, D. Mahadevan, H. Babiker +9 more
2023Journal for ImmunoTherapy of Cancer47 citations Open access
Semantic Scholar
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
J. Goldman, S. Eckhardt, M. Borad, K. Curtis +11 more
2014Clinical Cancer Research47 citations Open access
Semantic Scholar
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
J. Bendell, L. Rosen, R. Mayer, J. Goldman +6 more
2015Cancer Chemotherapy and Pharmacology46 citations Open access
Semantic Scholar
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET
J. Infante, T. Rugg, M. Gordon, I. Rooney +5 more
2013Investigational new drugs45 citations
Semantic Scholar
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
A. Tolcher, P. LoRusso, Jennifer Arzt, T. Busman +7 more
2015Cancer Chemotherapy and Pharmacology41 citations
Semantic Scholar
LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.
A. Patnaik, L. Rosen, S. Tolaney, A. Tolcher +14 more
201441 citations
Semantic Scholar
Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
A. Patnaik, L. Rosen, S. Tolaney, A. Tolcher +14 more
201439 citations
Semantic Scholar
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh, J. Hecht, L. Rosen, Z. Wainberg +11 more
2021Clinical Cancer Research35 citations
Semantic Scholar
A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
F. Meric-Bernstam, E. Calvo, V. Moreno, H. Chung +11 more
202031 citations
Semantic Scholar
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors
M. Mita, M. Gordon, L. Rosen, N. Kapoor +8 more
2014Cancer Chemotherapy and Pharmacology29 citations
Semantic Scholar
Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.
J. Goldman, L. Gandhi, A. Patnaik, L. Rosen +15 more
201428 citations
Semantic Scholar
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
C. Weekes, L. Rosen, A. Capasso, Kit Wong +13 more
2018Cancer Chemotherapy and Pharmacology23 citations
Semantic Scholar
Phase I Study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors
D. Hong, R. Said, G. Falchook, A. Naing +7 more
2013Clinical Cancer Research23 citations Open access
Semantic Scholar
Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib.
J. Goldberg, Tara Gavcovich, G. Saigal, J. Goldman +1 more
2014Journal of Clinical Oncology19 citations Open access
Semantic Scholar
A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).
K. Papadopoulos, M. Crittenden, M. Johnson, A. C. Lockhart +15 more
201618 citations
Semantic Scholar
Activity of larotrectinib in TRK fusion lung cancer.
A. Drilon, S. Kummar, V. Moreno, J. Patel +7 more
2019Annals of Oncology17 citations Open access
Semantic Scholar
First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.
J. Goldman, L. Rosen, A. Algazi, P. K. Turner +4 more
201317 citations
Semantic Scholar
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer
J. Goldman, L. Rosen, A. Tolcher, K. Papadopoulos +11 more
2017Investigational new drugs16 citations Open access
Semantic Scholar
A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.
G. Falchook, J. Goldman, J. Desai, I. Leitch +4 more
201416 citations
Semantic Scholar
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
V. Moreno, P. Garrido, K. Papadopoulos, M. D. De Miguel Luken +9 more
2021Lung Cancer15 citations
Semantic Scholar
A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).
Arun S. Singh, B. Chmielowski, J. Hecht, L. Rosen +11 more
2019Journal of Clinical Oncology14 citations
Semantic Scholar
762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)
G. Simon, V. Subbiah, L. Rosen, H. Lenz +8 more
2022Regular and Young Investigator Award Abstracts13 citations Open access
Semantic Scholar
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
G. Falchook, Xiao-Fei Zhou, K. Venkatakrishnan, R. Kurzrock +7 more
2015Drugs in R&D13 citations Open access
Semantic Scholar
Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer
S. Tolaney, L. Rosen, M. Beeram, J. Goldman +14 more
201512 citations
Semantic Scholar
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
D. Khalil, Isabel Prieto González-Albo, L. Rosen, T. Lillie +3 more
2023Investigational new drugs11 citations Open access
Semantic Scholar
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
V. Boni, H. Burris, Joyce F. Liu, A. Spira +16 more
202011 citations
Semantic Scholar
A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST).
Arun S. Singh, B. Chmielowski, J. Hecht, L. Rosen +7 more
201811 citations
Semantic Scholar
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT‐263), a dual inhibitor of Bcl‐2 and Bcl‐XL, in patients with cancer
Jian-Ning Yang, R. Pradhan, L. Rosen, A. Graham +2 more
2014Journal of Clinical Pharmacy and Therapeutics11 citations Open access
Semantic Scholar
A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors
N. Mostafa, Y. Chiu, L. Rosen, A. Bessudo +2 more
2014Cancer Chemotherapy and Pharmacology11 citations
Semantic Scholar
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
L. Rosen, L. Lipton, T. Price, N. Belman +8 more
2013BMC Cancer11 citations Open access
Semantic Scholar
Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort
Sarah D’Ambruoso, J. Glaspy, S. Hurvitz, N. Wenger +15 more
2021JCO Oncology Practice10 citations
Semantic Scholar
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
M. Saif, C. Becerra, M. Fakih, Wei-Jing Sun +13 more
2021Cancer Chemotherapy and Pharmacology9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Goldman×20
Invite
J. Goldman — researcher profile on SciRah
A. Tolcher×13
Invite
A. Tolcher — researcher profile on SciRah
K. Papadopoulos×12
Invite
K. Papadopoulos — researcher profile on SciRah
A. Patnaik×8
Invite
A. Patnaik — researcher profile on SciRah

×7

Invite

M. Beeram — researcher profile on SciRah

P. Kulanthaivel×7

Invite

P. Kulanthaivel — researcher profile on SciRah

Invite

E. Chan — researcher profile on SciRah

Invite

G. Shapiro — researcher profile on SciRah

Invite

S. Tolaney — researcher profile on SciRah

Invite

L. Gandhi — researcher profile on SciRah

Invite

D. Rasco — researcher profile on SciRah

Invite

D. Cronier — researcher profile on SciRah